Ads
related to: protein inhibitors and statins
Search results
Results From The WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy).
A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors in bladder cancer, a new study finds.
Ezetimibe is a selective cholesterol absorption inhibitor that inhibits the intestinal absorption of cholesterol by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal epithelium. [23]
The discovery of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors, called statins, was a breakthrough in the prevention of hypercholesterolemia and related diseases. Hypercholesterolemia is considered to be one of the major risk factors for atherosclerosis which often leads to cardiovascular , cerebrovascular and peripheral ...
Ezetimibe is a selective inhibitor of dietary cholesterol absorption. Lomitapide is a microsomal triglyceride transfer protein inhibitor. PCSK9 inhibitors [3] [4] are monoclonal antibodies for refractory cases. (e.g. Evolocumab, Inclisiran) They are used in combination with statins. Probucol (withdrawn in several countries)
These protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors that have been developed and are currently used in clinical practice include:
Proprotein convertases have medical significance, because they are involved in many important biological processes, such as cholesterol synthesis. [2] Compounds called proprotein convertase inhibitors can block their action, and block the target proteins from becoming active.
When best-selling cholesterol drug Lipitor fell off the patent cliff in 2011, the question became, "What's next?" A hot new class of treatments called PCSK9 inhibitors want to become the answer.